<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219400</url>
  </required_header>
  <id_info>
    <org_study_id>103</org_study_id>
    <nct_id>NCT01219400</nct_id>
  </id_info>
  <brief_title>Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes</brief_title>
  <official_title>Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore whether the novel therapy of type 2 diabetes,
      vildagliptin, which inhibits dipeptidyl peptidase-4 (DPP-4), affects glucagon
      counterregulation during hypoglycemia in insulin-treated patients with type 2 diabetes.
      Vildagliptin is given, together with the on-going insulin therapy, for one month, whereafter
      hypoglycemia is induced under standardized conditions, and the glucagon response is
      determined, and compared to that after a month of placebo treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vildagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4) and inhibits glucagon
      secretion and stimulates insulin secretion. This improves glycemia in subjects with type 2
      diabetes with a very low risk for hypoglycemia. If hypoglycemia nevertheless develops, it is
      important that vildagliptin under such conditions does not inhibit glucagon secretion, since
      that would aggravate the hypoglycemia. It was indeed previously demonstrated in type 2
      diabetes that vildagliptin dos not inhibit glucagon secretion during hypoglycemia. This study
      explores whether vildagliptin affects glucagon counterregulation during hypoglycemia in
      insulin-treated patients of type 2 diabetes. Vildagliptin is given, together with the
      on-going insulin therapy, for one month, whereafter hypoglycemia is induced under
      standardized conditions, and the glucagon response is determined, and compared to that after
      a month of placebo treatment. The hypoglycemia is induced bvy a standardized clamp procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon response to hypoglycemia</measure>
    <time_frame>45 min</time_frame>
    <description>Change in glucagon from before hypoglycemia clamp until after 45 min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catecholamine response to hypoglycemia</measure>
    <time_frame>45 min</time_frame>
    <description>Change in catecholamines from before hypoglycemic clamp to 45 min</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin (50 mg BID) given for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin (50 mg BID) given for four weeks</description>
    <arm_group_label>Vildagliptin</arm_group_label>
    <other_name>Galvus</other_name>
    <other_name>274901-16-5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Insulin treatment

          -  Age &gt;18 years

          -  HbA1c &lt;=8.5%

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Acute infection

          -  Liver disease

          -  Treatment with cortisol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Ahr√©n, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lund University</name>
      <address>
        <city>Lund</city>
        <zip>22184</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Bo Ahren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>DPP-4</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Catecholamines</keyword>
  <keyword>Counterregulation</keyword>
  <keyword>Insulin-treatment</keyword>
  <keyword>Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

